Mangoceuticals, Inc. (NASDAQ:MGRX) Short Interest Down 51.3% in April

Mangoceuticals, Inc. (NASDAQ:MGRX) saw a large decrease in short interest in April. As of April 30th, there was short interest totaling 451,464 shares, a decrease of 51.3% from the April 15th total of 926,613 shares. Approximately 3.2% of the company’s stock are short sold. Based on an average daily volume of 563,464 shares, the days-to-cover ratio is currently 0.8 days.

Mangoceuticals Trading Up 11.9%

Shares of MGRX traded up $0.05 on Friday, reaching $0.44. The company’s stock had a trading volume of 798,966 shares, compared to its average volume of 812,643. Mangoceuticals has a twelve month low of $0.16 and a twelve month high of $2.75. The stock has a market capitalization of $7.47 million, a PE ratio of -0.17 and a beta of 2.12. The firm has a fifty day moving average of $0.38 and a 200-day moving average of $0.73.

Mangoceuticals (NASDAQ:MGRX) last posted its earnings results on Wednesday, April 1st. The company reported $0.13 earnings per share for the quarter. Mangoceuticals had a negative net margin of 4,536.70% and a negative return on equity of 109.38%. The company had revenue of $0.09 million for the quarter.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MGRX. Wall Street Zen raised shares of Mangoceuticals to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Mangoceuticals has a consensus rating of “Sell”.

Institutional Investors Weigh In On Mangoceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC acquired a new stake in shares of Mangoceuticals in the 4th quarter worth about $1,137,000. Ikarian Capital LLC acquired a new stake in shares of Mangoceuticals in the 4th quarter worth about $102,000. Jane Street Group LLC acquired a new stake in shares of Mangoceuticals in the 4th quarter worth about $35,000. Boothbay Fund Management LLC acquired a new stake in shares of Mangoceuticals in the 4th quarter worth about $28,000. Finally, Virtu Financial LLC acquired a new stake in shares of Mangoceuticals in the 4th quarter worth about $25,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.